7210 Wareham Drive, Tampa, FL 33647
April 2, 2025 Robard, the medical weight loss company, has begun selling its shakes, puddings, soups and beverages direct to the public via a new website. These products are part of its New Direction program. This is a departure from its long-standing policy where you had to sign up for the program to get access […]
Robard Begins Selling Diet Foods Direct to Consumers Read More »
March 31, 2025 Many economists and analysts are saying that a recession is coming sometime this year. That said, many weight loss companies and their top managers will say they’ll have to cut expenses, especially marketing. That’s the knee-jerk reaction, but it’s dead wrong. When consumers cut back on spending, they will revert to trusted
A Recession Is NOT The Time To Cut Marketing Read More »
March 24, 2025 Marketdata LLC has just published a new report: “The U.S. Weight Loss Market: Commercial (non-medical) Programs & Products”, March 2025. This is a 220-page analysis of commercial weight loss programs/companies and how they have been affected by and respond to the onslaught of the GLP-1 drugs competition. The $38 billion U.S. commercial weight loss
$38.4 Billion U.S. Commercial Weight Loss Market Pivots To Survive GLP-1 Drugs Explosion Read More »
March 14, 2025 On Mar. 5, a judge denied a request from the Outsourcing Facilities Association (OFA), an industry group for compounding pharmacies, to block the FDA’s attempt to stop the production of compounded tirzepatide. Generally, making copies of brand-name drugs is not legal until their patents expire. But there are exceptions: Compounding pharmacies can
FDA Says No More Compounded Weight Loss Drugs – Industry OFA Appeal Shot Down Read More »
March 13, 2025 Marketdata, the parent company of DietBusinessWatch.com, has updated its report on the Commercial & Retail Weight Loss Market. Several things have become apparent as we do the research Marketdata analysts see a possible opportunity this year for the commercial (non-medical) weight loss firms to recover some ground. Here’s how we think 2025
Recession Is Coming – But Commercial Diet Companies Could Benefit Read More »
March 5, 2025 Weight loss drugs (GLP-1s) have soared in popularity over the last two years, with about 12% of American adults reporting that they’ve used a medication like Ozempic, Wegovy or Mounjaro to slim down. That’s a big slice of the population — and new research shows that being on these medications influences what
GLP-1 Drugs Are Affecting Consumers’ Food Spending Habits Read More »
Feb. 27, 2025 WW reported its Q4 and full year 2024 results today. The company’s Board of Directors named Interim President and CEO Tara Comonte, to a permanent role as President and CEO, effective February 26, 2025. “We are pleased with the momentum in our Clinical business in the Fourth Quarter, reflecting the increasing demand
Weight Watchers Reports Q4 and 2024 Yearly Results Read More »
Feb. 27, 2025 Marketdata LLC has published anew 154-page analysis of the U.S. weight loss market, entitled: “The U.S. Medical Weight Loss Market: The Impact of GLP-1 Drugs on Doctors, Hospitals, Clinics and Franchises”, February 2025. This report presents a complete picture of the medical weight loss market in the United States, with the inter-relationships between competing
$33 Billion U.S. Medical Weight Loss Market Dominated by GLP-1 Drugs – New Report Read More »
Feb. 25, 2025 Eli Lilly said today that it will offer more doses of its obesity drug Zepbound in vials and lower the prices of the doses it already sells, as the pharma giant seeks to draw patients away from cheap, compounded copies of weight loss medications. Zepbound was originally sold in injectable pens at
Eli Lilly To Lower Price of Zepbound Vials, GLP-1 Shortage Is Over Read More »
Feb. 2o, 2025 Herbalife reported Q4 and full year 2024 results. The company sells a significant amount of weight loss and meal replacement products each year. “With three consecutive quarters of new distributor growth, a new incoming CEO and significantly improved Adjusted EBITDA2 margins, we enter 2025 with strong momentum.” – Michael Johnson, Chairman and
Herbalife Reports 2024 Results, $567 Million Weight Loss U.S. Sales Read More »